Aman Chauhan

Prof. Dr. Aman Chauhan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
UVUlka N Vaishampayan
Ulka N Vaishampayan
JMJameel Muzaffar
Jameel Muzaffar
IWIra S. Winer
Ira S. Winer
SRSeth D Rosen
Seth D Rosen
Christopher HoimesChristopher Hoimes
Christopher Hoimes
VVVamsidhar Velcheti
Vamsidhar Velcheti
Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8+ T cells and natural killer cells, with minimal expansion of regulatory T cells, thereby mitigating the risk of toxicities associated with high-affinity interleukin-2 receptor activation. Clinical outcomes with nemvaleukin are unknown. ARTISTRY-1 investigated the safety, recommended phase 2 dose (RP2D), and antitumor activity of nemvaleukin in patients with advanced solid tumors. Methods: This was a three-part, open-label, phase 1/2 study: part A, dose-escalation monotherapy, part B, dose-expansion monotherapy, and part C, combination therapy with pembrolizumab. The study was conducted at 32 sites in 7 countries. Adult patients with advanced solid tumors were enrolled and received intravenous nemvaleukin once daily on days 1–5 (21-day cycle) at 0.1–10 µg/kg/day (part A), or at the RP2D (part B), or with pembrolizumab (part C). Primary endpoints were RP2D selection and dose-limiting toxicities (part A), and overall response rate (ORR) and safety (parts B and C). Results: From July 2016 to March 2023, 243 patients were enrolled and treated (46, 74, and 166 in parts A, B, and C, respectively). The maximum tolerated dose was not reached. RP2D was determined as 6 µg/kg/day. ORR with nemvaleukin monotherapy was 10% (7/68; 95% CI 4 to 20), with seven partial responses (melanoma, n=4; renal cell carcinoma, n=3). Robust CD8+ T and natural killer cell expansion, and minimal regulatory T cell expansion were observed following nemvaleukin treatment. ORR with nemvaleukin plus pembrolizumab was 13% (19/144; 95% CI 8 to 20), with 5 complete and 14 partial responses; 6 responses were in PD-(L)1 inhibitor-approved and five in PD-(L)1 inhibitor-unapproved tumor types. Three responses were in patients with platinum-resistant ovarian cancer. The most common grade 3–4 treatment-related adverse events (TRAEs) in parts B and C, respectively, were neutropenia (49%, 21%) and anemia (10%, 11%); 4% of patients in each part discontinued due to TRAEs. Conclusions: Nemvaleukin was well tolerated and demonstrated promising antitumor activity across heavily pretreated advanced solid tumors. Phase 2/3 studies of nemvaleukin are ongoing. Trial registration number: NCT02799095.

15 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
QYQian Yu
Qian Yu
FCFan Cao
Fan Cao
PHPeter J Hosein
Peter J Hosein
BHBin Huang
Bin Huang
PPPaulo Pinheiro
Paulo Pinheiro
Aman ChauhanAman Chauhan
Aman Chauhan
Importance: Neuroendocrine tumors (NETs) have traditionally been considered rare (orphan) diseases; however, improvements in diagnostic methods and heightened awareness about NETs may have altered their epidemiologic profile in the U.S. Objective: To evaluate trends in incidence, prevalence, and survival of NETs in the United States from 2000 to 2021 using updated data from the SEER-22 registry. Method: This population-based, retrospective cohort study used the SEER-22 database for incidence, prevalence, and survival analyses. Data included 231,659 patients diagnosed with NETs between 2000 and 2021. Age-adjusted incidence, limited-duration prevalence, 5-year overall survival (OS), and hazard ratios (HRs) for survival by grade, stage, year of diagnosis, race, and primary site were investigated. Results: From 2000 to 2021, NET incidence nearly doubled, from 4.6 to 8.2 per 100,000 persons. The prevalence in 2021 reached 0.064%, with grade 1 tumors showing the steepest increase. Five-year OS was 77.4% overall and highest among localized NETs (82.3%) and grade 1 tumors (80.0%). Multivariable analysis showed improved survival over time (HR for 2015–2021 vs. 2000–2004, 0.92; 95% CI, 0.89–0.95). Black and American Indian/Alaska Native patients had significantly worse outcomes than White patients. Conclusions and Relevance: NETs are no longer orphan diseases based on current U.S. incidence and prevalence trends. With increasing survival and patient numbers, there is an urgent need for expanded multidisciplinary NET care and research efforts focused on survivorship and quality of life.

14 November 2023 in Cells
Verified
Journal Article
Open access
PDF file
SKSamuel Kareff
Samuel Kareff
VCVirginia Corbett
Virginia Corbett
PHPaul Leon Hallenbeck
Paul Leon Hallenbeck
Aman ChauhanAman Chauhan
Aman Chauhan
The TEM8 protein represents an emerging biomarker in many solid tumor histologies. Given the various roles it plays in oncogenesis, including but not limited to angiogenesis, epithelial-to-mesenchymal transition, and cell migration, TEM8 has recently served and will continue to serve as the target of novel oncologic therapies. We review herein the role of TEM8 in oncogenesis. We review its normal function, highlight the additional roles it plays in the tumor microenvironment, and synthesize pre-clinical and clinical data currently available. We underline the protein’s prognostic and predictive abilities in various solid tumors by (1) highlighting its association with more aggressive disease biology and poor clinical outcomes and (2) assessing its associated clinical trial landscape. Finally, we offer future directions for clinical studies involving TEM8, including incorporating pre-clinical agents into clinical trials and combining previously tested oncologic therapies with currently available treatments, such as immunotherapy.

1 October 2023 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
VCVirginia Corbett
Virginia Corbett
DLDaneng Li
Daneng Li
Aman ChauhanAman Chauhan
Aman Chauhan
Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers

2 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CKCharles Kunos
Charles Kunos
MMMolly E. Martin
Molly E. Martin
MGMichalis F Georgiou
Michalis F Georgiou
RKRuss Kuker
Russ Kuker
Aman ChauhanAman Chauhan
Aman Chauhan
Radiation oncologists, radiopharmacists, nuclear medicine physicians, and medical oncologists have seen a renewed clinical interest in radiopharmaceuticals for the curative or the palliative treatment of cancer. To allow for the discovery and the clinical advancement of targeted radiopharmaceuticals, these stakeholders have reformed their trial efforts and remodeled their facilities to accommodate the obligations of a program centered upon radioactive investigational drug products. Now considered informally as drugs and not beam radiotherapy, radiopharmaceuticals can be more easily studied in the traditional clinical trial enterprise ranging from phase 0–I to phase III studies. Resources and physical facilities allocated to radiopharmaceuticals have brought forth new logistics and patient experience for safe and satisfactory drug delivery. The clinical use of theranostic agents—that is, diagnostic and therapeutic radionuclide pairs—has accelerated radiopharmaceutical development.

1 January 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
VCVirginia Corbett
Virginia Corbett
TSTriparna Sen
Triparna Sen
Aman ChauhanAman Chauhan
Aman Chauhan
Role of CDK4/6 inhibitors in targeting Rb proficient small cell lung cancer